Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome
Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, pres...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
E. A. Troshina [verfasserIn] Р. A. Terekhov [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Russisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Ожирение и метаболизм ; 20(2023), 1, Seite 84-91 volume:20 ; year:2023 ; number:1 ; pages:84-91 |
|---|
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.14341/omet12980 |
|---|
| Katalog-ID: |
DOAJ096082690 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096082690 | ||
| 003 | DE-627 | ||
| 005 | 20240413141300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14341/omet12980 |2 doi | |
| 035 | |a (DE-627)DOAJ096082690 | ||
| 035 | |a (DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a QP1-981 | |
| 050 | 0 | |a QD415-436 | |
| 100 | 0 | |a E. A. Troshina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. | ||
| 650 | 4 | |a hypogonadism | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a abdominal obesity | |
| 650 | 4 | |a metabolic syndrome | |
| 650 | 4 | |a testosterone | |
| 650 | 4 | |a cardio-metabolic risk | |
| 653 | 0 | |a Physiology | |
| 653 | 0 | |a Biochemistry | |
| 700 | 0 | |a Р. A. Terekhov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Ожирение и метаболизм |g 20(2023), 1, Seite 84-91 |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:1 |g pages:84-91 |
| 856 | 4 | 0 | |u https://doi.org/10.14341/omet12980 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.omet-endojournals.ru/jour/article/view/13000 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2071-8713 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2306-5524 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 1 |h 84-91 | ||
| author_variant |
e a t eat р a t рat |
|---|---|
| matchkey_str |
eatroshinaaterekhov:2023----:yooaimnvseaoeiyneaeulldecmoeto |
| hierarchy_sort_str |
2023 |
| callnumber-subject-code |
QP |
| publishDate |
2023 |
| allfields |
10.14341/omet12980 doi (DE-627)DOAJ096082690 (DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35 DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Troshina verfasserin aut Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. hypogonadism obesity abdominal obesity metabolic syndrome testosterone cardio-metabolic risk Physiology Biochemistry Р. A. Terekhov verfasserin aut In Ожирение и метаболизм 20(2023), 1, Seite 84-91 volume:20 year:2023 number:1 pages:84-91 https://doi.org/10.14341/omet12980 kostenfrei https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35 kostenfrei https://www.omet-endojournals.ru/jour/article/view/13000 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2023 1 84-91 |
| spelling |
10.14341/omet12980 doi (DE-627)DOAJ096082690 (DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35 DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Troshina verfasserin aut Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. hypogonadism obesity abdominal obesity metabolic syndrome testosterone cardio-metabolic risk Physiology Biochemistry Р. A. Terekhov verfasserin aut In Ожирение и метаболизм 20(2023), 1, Seite 84-91 volume:20 year:2023 number:1 pages:84-91 https://doi.org/10.14341/omet12980 kostenfrei https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35 kostenfrei https://www.omet-endojournals.ru/jour/article/view/13000 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2023 1 84-91 |
| allfields_unstemmed |
10.14341/omet12980 doi (DE-627)DOAJ096082690 (DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35 DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Troshina verfasserin aut Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. hypogonadism obesity abdominal obesity metabolic syndrome testosterone cardio-metabolic risk Physiology Biochemistry Р. A. Terekhov verfasserin aut In Ожирение и метаболизм 20(2023), 1, Seite 84-91 volume:20 year:2023 number:1 pages:84-91 https://doi.org/10.14341/omet12980 kostenfrei https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35 kostenfrei https://www.omet-endojournals.ru/jour/article/view/13000 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2023 1 84-91 |
| allfieldsGer |
10.14341/omet12980 doi (DE-627)DOAJ096082690 (DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35 DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Troshina verfasserin aut Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. hypogonadism obesity abdominal obesity metabolic syndrome testosterone cardio-metabolic risk Physiology Biochemistry Р. A. Terekhov verfasserin aut In Ожирение и метаболизм 20(2023), 1, Seite 84-91 volume:20 year:2023 number:1 pages:84-91 https://doi.org/10.14341/omet12980 kostenfrei https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35 kostenfrei https://www.omet-endojournals.ru/jour/article/view/13000 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2023 1 84-91 |
| allfieldsSound |
10.14341/omet12980 doi (DE-627)DOAJ096082690 (DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35 DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Troshina verfasserin aut Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. hypogonadism obesity abdominal obesity metabolic syndrome testosterone cardio-metabolic risk Physiology Biochemistry Р. A. Terekhov verfasserin aut In Ожирение и метаболизм 20(2023), 1, Seite 84-91 volume:20 year:2023 number:1 pages:84-91 https://doi.org/10.14341/omet12980 kostenfrei https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35 kostenfrei https://www.omet-endojournals.ru/jour/article/view/13000 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2023 1 84-91 |
| language |
English Russian |
| source |
In Ожирение и метаболизм 20(2023), 1, Seite 84-91 volume:20 year:2023 number:1 pages:84-91 |
| sourceStr |
In Ожирение и метаболизм 20(2023), 1, Seite 84-91 volume:20 year:2023 number:1 pages:84-91 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
hypogonadism obesity abdominal obesity metabolic syndrome testosterone cardio-metabolic risk Physiology Biochemistry |
| isfreeaccess_bool |
true |
| container_title |
Ожирение и метаболизм |
| authorswithroles_txt_mv |
E. A. Troshina @@aut@@ Р. A. Terekhov @@aut@@ |
| publishDateDaySort_date |
2023-01-01T00:00:00Z |
| id |
DOAJ096082690 |
| language_de |
englisch russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096082690</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413141300.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/omet12980</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096082690</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP1-981</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD415-436</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. A. Troshina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypogonadism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">abdominal obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metabolic syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">testosterone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardio-metabolic risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Physiology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biochemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Р. A. Terekhov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Ожирение и метаболизм</subfield><subfield code="g">20(2023), 1, Seite 84-91</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:84-91</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/omet12980</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.omet-endojournals.ru/jour/article/view/13000</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2071-8713</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2306-5524</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="h">84-91</subfield></datafield></record></collection>
|
| callnumber-first |
Q - Science |
| author |
E. A. Troshina |
| spellingShingle |
E. A. Troshina misc QP1-981 misc QD415-436 misc hypogonadism misc obesity misc abdominal obesity misc metabolic syndrome misc testosterone misc cardio-metabolic risk misc Physiology misc Biochemistry Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome |
| authorStr |
E. A. Troshina |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
QP1-981 |
| illustrated |
Not Illustrated |
| topic_title |
QP1-981 QD415-436 Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome hypogonadism obesity abdominal obesity metabolic syndrome testosterone cardio-metabolic risk |
| topic |
misc QP1-981 misc QD415-436 misc hypogonadism misc obesity misc abdominal obesity misc metabolic syndrome misc testosterone misc cardio-metabolic risk misc Physiology misc Biochemistry |
| topic_unstemmed |
misc QP1-981 misc QD415-436 misc hypogonadism misc obesity misc abdominal obesity misc metabolic syndrome misc testosterone misc cardio-metabolic risk misc Physiology misc Biochemistry |
| topic_browse |
misc QP1-981 misc QD415-436 misc hypogonadism misc obesity misc abdominal obesity misc metabolic syndrome misc testosterone misc cardio-metabolic risk misc Physiology misc Biochemistry |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Ожирение и метаболизм |
| hierarchy_top_title |
Ожирение и метаболизм |
| isfreeaccess_txt |
true |
| title |
Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome |
| ctrlnum |
(DE-627)DOAJ096082690 (DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35 |
| title_full |
Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome |
| author_sort |
E. A. Troshina |
| journal |
Ожирение и метаболизм |
| journalStr |
Ожирение и метаболизм |
| callnumber-first-code |
Q |
| lang_code |
eng rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
84 |
| author_browse |
E. A. Troshina Р. A. Terekhov |
| container_volume |
20 |
| class |
QP1-981 QD415-436 |
| format_se |
Elektronische Aufsätze |
| author-letter |
E. A. Troshina |
| doi_str_mv |
10.14341/omet12980 |
| author2-role |
verfasserin |
| title_sort |
hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome |
| callnumber |
QP1-981 |
| title_auth |
Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome |
| abstract |
Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. |
| abstractGer |
Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. |
| abstract_unstemmed |
Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome |
| url |
https://doi.org/10.14341/omet12980 https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35 https://www.omet-endojournals.ru/jour/article/view/13000 https://doaj.org/toc/2071-8713 https://doaj.org/toc/2306-5524 |
| remote_bool |
true |
| author2 |
Р. A. Terekhov |
| author2Str |
Р. A. Terekhov |
| callnumber-subject |
QP - Physiology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.14341/omet12980 |
| callnumber-a |
QP1-981 |
| up_date |
2024-07-03T18:12:11.880Z |
| _version_ |
1803582525287694336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096082690</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413141300.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/omet12980</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096082690</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ16d6ac3730ac4e0fbf01a742c8db5e35</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP1-981</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD415-436</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. A. Troshina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypogonadism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">abdominal obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metabolic syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">testosterone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardio-metabolic risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Physiology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biochemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Р. A. Terekhov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Ожирение и метаболизм</subfield><subfield code="g">20(2023), 1, Seite 84-91</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:84-91</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/omet12980</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/16d6ac3730ac4e0fbf01a742c8db5e35</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.omet-endojournals.ru/jour/article/view/13000</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2071-8713</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2306-5524</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="h">84-91</subfield></datafield></record></collection>
|
| score |
7.400996 |